Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
Public ClinicalTrials.gov record NCT02846324. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized, Placebo-Controlled Study of GBT440 to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF subjects will be randomized to receive GBT440 or Placebo orally daily.
Study identification
- NCT ID
- NCT02846324
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 39 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 45 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2016 (Type not available)
- Primary completion
- Sep 2017 (Actual)
- Completion
- Nov 2017 (Actual)
- Last update posted
- Oct 20, 2020
2016 – 2017
United States locations
- U.S. sites
- 12
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35233 | — |
| Not listed | San Francisco | California | 94143 | — |
| Not listed | Denver | Colorado | 80206 | — |
| Not listed | Miami | Florida | 33136 | — |
| Not listed | Kansas City | Kansas | 66160 | — |
| Not listed | New Orleans | Louisiana | 70122 | — |
| Not listed | New York | New York | 10032 | — |
| Not listed | Philadelphia | Pennsylvania | 19145 | — |
| Not listed | Charleston | South Carolina | 29425 | — |
| Not listed | Nashville | Tennessee | 37212 | — |
| Not listed | Salt Lake City | Utah | 84108 | — |
| Not listed | Falls Church | Virginia | 22042 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02846324, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2020 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02846324 live on ClinicalTrials.gov.